Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report sales of $2.98 million for the current quarter, according to Zacks. Three analysts have provided estimates for Strongbridge Biopharma’s earnings, with the highest sales estimate coming in at $3.29 million and the lowest estimate coming in at $2.43 million. The firm is scheduled to report its next earnings report on Monday, March 26th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full year sales of $2.98 million for the current fiscal year, with estimates ranging from $6.49 million to $7.35 million. For the next financial year, analysts forecast that the business will report sales of $14.04 million per share, with estimates ranging from $9.39 million to $21.91 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.07.

Several research firms recently issued reports on SBBP. BidaskClub downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Zacks Investment Research cut Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Finally, Cantor Fitzgerald set a $14.00 price objective on Strongbridge Biopharma and gave the company a “buy” rating in a research note on Wednesday, January 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $12.81.

A number of large investors have recently modified their holdings of the business. Paloma Partners Management Co bought a new position in Strongbridge Biopharma during the 4th quarter valued at $152,000. Perceptive Advisors LLC bought a new position in Strongbridge Biopharma during the 4th quarter valued at $1,994,000. Goldman Sachs Group Inc. bought a new position in Strongbridge Biopharma during the 4th quarter valued at $272,000. Deutsche Bank AG lifted its stake in Strongbridge Biopharma by 185.0% during the 4th quarter. Deutsche Bank AG now owns 55,711 shares of the biotechnology company’s stock valued at $403,000 after acquiring an additional 36,160 shares in the last quarter. Finally, Armistice Capital LLC lifted its stake in Strongbridge Biopharma by 69.4% during the 4th quarter. Armistice Capital LLC now owns 2,870,000 shares of the biotechnology company’s stock valued at $20,808,000 after acquiring an additional 1,175,400 shares in the last quarter. Institutional investors and hedge funds own 57.01% of the company’s stock.

Strongbridge Biopharma (NASDAQ SBBP) traded down $0.25 during midday trading on Friday, reaching $6.55. 155,288 shares of the company traded hands, compared to its average volume of 342,974. Strongbridge Biopharma has a twelve month low of $2.35 and a twelve month high of $9.02. The company has a current ratio of 4.70, a quick ratio of 4.61 and a debt-to-equity ratio of -1.89. The firm has a market cap of $300.30 and a P/E ratio of -1.94.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 Million” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/02/15/analysts-expect-strongbridge-biopharma-plc-sbbp-will-announce-quarterly-sales-of-2-98-million.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.